Hatteras Venture Partners related stories
All articles and analysis
Qvella nets $20 mln in Series A round co-led by RA Capital, WhitecapQvella, a Canadian molecular diagnostics company, has secured US$20 million in Series A financing. The round was co-led by U.S. healthcare investor RA Capital Management and Canadian venture capital firm Whitecap Venture Partners, and was joined by Hatteras Venture Partners and Sands Capital Ventures. Toronto-based Qvella is a developer of pathogen detection technology that obtains more time-efficient diagnostic results. Led by President and CEO Tino Alavie, the company plans to use the new funding to support on-going product development and expansion of its team. Whitecap announced a pre-Series A investment /canada/2015/06/23/whitecap-venture-partners-fund-iii-raises-100-mln-invests-in-qvella/ in Qvella when the firm closed Whitecap III LP at $100 million in June.
Fundraising recap Sep 21, 2015San Francisco-based firm seeks cloud business apps; 500 closes one fund and plans another; and other fundraising briefs worldwide
Patient engagement platform Medfusion reels in $3 mlnCary, North Carolina-based patient engagement platform Medfusion Inc has raised $3 million in funding. The investors were Bull City Venture Partners and Hatteras Venture Partners. In conjunction with the funding, David Jones of Bull City Venture Partners and John Crumpler of Hatteras Venture Partners have been appointed to Medfusion's board.
- Hatteras raises $91 mln toward fifth fund
Hatteras Venture Partners has raised $91 million toward a fifth fund, according to an SEC filing. The fund target is $150 million, according to the filing.
- Malin Corp invests in Hatteras Venture Partners and Jaan Health
Irish global life sciences company Malin Corp has agreed to invest $15 million in North Carolina-based Hatteras Venture Partners, a venture firm that focuses on early-stage companies in life sciences. The investment could hike up to $20 million "depending on a number of factors." Also, Malin has agreed to invest up to $1 million in New York-based healthcare mobile tech company Jaan Health. In addition to the investments, Malin CEO Adrian Howd will become the company's chief investment officer while remaining on the company's board of directors. And, Kelly Martin, who's currently on Malin's board of directors, will step into the Malin CEO position.
- NuSirt takes in $6 mln Series C
Nashville-based NuSirt Biopharma, which focuses on helping people with chronic metabolic diseases, has secured $6 million in Series C funding. The investors included Hatteras Venture Partners, Mountain Group Partners and TriStar Technology Ventures.
- Spyryx Biosciences rakes in $18 mln Series A
Research Triangle Park, North Carolina-based Spyryx Biosciences, which develops treatments for respiratory diseases, has raised $18 million in Series A funding. The investors were Canaan Partners, Hatteras Venture Partners and 5AM Ventures. In conjunction with the funding, Dr. Tim Shannon, general partner of Canaan, has been named chairman of Spyryx's board of directors. Also, Dr. Christy Shaffer, managing director of Hatteras Discovery at Hatteras and Dr. Brian Daniels, venture partner of 5AM, have been added to Spyryx's board of directors.
- Hatteras Venture leads $5.6 mln funding in Contego Medical
Hatteras Venture Partners has led a $5.6 million Series B funding in medical device maker Contego Medical. Other participants in the funding round include Mountain Group Partners, Lookout Capital and Medical Mutual.
- PhaseBio Pharmaceuticals picks up $40 mln Series C
Malvern, Pennsylvania-based PhaseBio Pharmaceuticals Inc, which is focused on developing treatments for metabolic and specialty cardiopulmonary disorders, has secured $40 million in Series C funding. AstraZeneca led the round with participation from New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC and Fletcher Spaght Ventures. In addition to the funding, Dr. Michael Gutch of AstraZeneca has been added to PhaseBio's board of directors while Donald Dwyer, also of AstraZeneca, has become a board observer.
- Biotech company ORIG3N scores $3.1 mln
Boston-based biotech company ORIG3N has closed $3.1 million in funding. The investors included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.